Medical Care Cost of Oropharyngeal Cancer Among Texas Patients

Overview

Journal Cancer Epidemiol Biomarkers Prev

Specialties Biochemistry
Oncology
Public Health

Date 2017 Aug 26

PMID 28838945

Citations 15

Authors

David R Lairson

Chi-Fang Wu

Wenyaw Chan

Kristina R Dahlstrom

Samantha Tam

Erich M Sturgis

Affiliations

Soon will be listed here.

Abstract

The incidence of oropharyngeal cancer is rising rapidly, with the majority of cases being attributable to human papillomavirus (HPV). Despite the availability of a vaccine, rates of HPV vaccination among Texas youth are low. The healthcare cost of oropharyngeal cancer in Texas is unknown. The aims of this study were to estimate the first 2-year cost of treating new cases of oropharyngeal cancer and determine the predictors of oropharyngeal cancer treatment cost in Texas. This study included a retrospective cohort of 467 Texas patients with commercial insurance claims data with oropharyngeal cancer diagnosed from 2011 to 2014 and a control group of 467 noncancer patients obtained with propensity score matching. Total healthcare cost during the first 2 years after the index date was measured. A generalized linear model was used to identify predictors of monthly cost during the 2 years after the index date. The mean differential adjusted healthcare cost for oropharyngeal cancer cases was $139,749 in the first 2 years. The mean adjusted monthly cost in the first 2 years was $6,693 for cases and $870 for controls. Age, comorbidity, mental health, prediagnostic healthcare cost, and time index were significant predictors of monthly cost. Medical care cost was about $140,000 in the first 2 years after diagnosis of oropharyngeal cancer among commercially insured patients in Texas. The cost estimates provide important parameters for development of decision-analytic models to inform decision makers about the potential value of initiatives for increasing the HPV immunization rate in the state. .

Citing Articles

Path analysis of factors influencing length of stay and hospitalisation expenses for oral cancer patients in tertiary hospitals in southeastern China: a cross-sectional study.

Fan Y, Yang Q, Chen C, Hu X, Xu M, Weng Y BMJ Open. 2025; 15(1):e087060.

PMID: 39863415 PMC: 11784420. DOI: 10.1136/bmjopen-2024-087060.

Impacts of the US CDC recommendation on human papillomavirus vaccine uptake, 2010-2015.

Ghosh P, Chaudhry A, Campbell J, Kim M, Smith K, Demir F Front Public Health. 2025; 12:1464685.

PMID: 39744345 PMC: 11689657. DOI: 10.3389/fpubh.2024.1464685.

Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States.

Clay P, Thompson T, Markowitz L, Ekwueme D, Saraiya M, Chesson H Vaccine. 2023; 41(14):2376-2381.

PMID: 36907737 PMC: 10198126. DOI: 10.1016/j.vaccine.2023.02.049.

Understanding Financial Toxicity in Patients with Head and Neck Cancer: A Systematic Review.

Rosi-Schumacher M, Patel S, Phan C, Goyal N Clin Med Insights Oncol. 2023; 17:11795549221147730.

PMID: 36710886 PMC: 9880590. DOI: 10.1177/11795549221147730.

The cost of oral cancer: A systematic review.

Ribeiro-Rotta R, Rosa E, Milani V, Dias N, Masterson D, Silva E PLoS One. 2022; 17(4):e0266346.

PMID: 35446870 PMC: 9022815. DOI: 10.1371/journal.pone.0266346.

References

Saraiya M, Unger E, Thompson T, Lynch C, Hernandez B, Lyu C . US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015; 107(6):djv086. PMC: 4838063. DOI: 10.1093/jnci/djv086. View

Ekwueme D, Chesson H, Zhang K, Balamurugan A . Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis-United States, 2003. Cancer. 2008; 113(10 Suppl):2936-45. DOI: 10.1002/cncr.23761. View

Chesson H, Ekwueme D, Saraiya M, Watson M, Lowy D, Markowitz L . Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012; 30(42):6016-9. PMC: 6629018. DOI: 10.1016/j.vaccine.2012.07.056. View

Coughlan D, Frick K . Economic impact of human papillomavirus-associated head and neck cancers in the United States. Otolaryngol Clin North Am. 2012; 45(4):899-917. DOI: 10.1016/j.otc.2012.05.002. View

Hu D, Goldie S . The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008; 198(5):500.e1-7. PMC: 2441758. DOI: 10.1016/j.ajog.2008.03.064. View

Bessell A, Glenny A, Furness S, Clarkson J, Oliver R, Conway D . Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database Syst Rev. 2011; (9):CD006205. DOI: 10.1002/14651858.CD006205.pub3. View

Yamaoka K, Nakagawa T, Uno T . Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978; 6(2):165-75. DOI: 10.1007/BF01117450. View

Borggreven P, Aaronson N, Verdonck-de Leeuw I, Muller M, Heiligers M, de Bree R . Quality of life after surgical treatment for oral and oropharyngeal cancer: a prospective longitudinal assessment of patients reconstructed by a microvascular flap. Oral Oncol. 2007; 43(10):1034-42. DOI: 10.1016/j.oraloncology.2006.11.017. View

Hollenbeak C, Kulaylat A, Mackley H, Koch W, Schaefer E, Goldenberg D . Determinants of Medicare Costs for Elderly Patients With Oral Cavity and Pharyngeal Cancers. JAMA Otolaryngol Head Neck Surg. 2015; 141(7):628-35. DOI: 10.1001/jamaoto.2015.0940. View

10.

Lingen M, Xiao W, Schmitt A, Jiang B, Pickard R, Kreinbrink P . Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol. 2012; 49(1):1-8. DOI: 10.1016/j.oraloncology.2012.07.002. View

11.

Lang K, Menzin J, Earle C, Jacobson J, Hsu M . The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg. 2004; 130(11):1269-75. DOI: 10.1001/archotol.130.11.1269. View

12.

Belcher R, Hayes K, Fedewa S, Chen A . Current treatment of head and neck squamous cell cancer. J Surg Oncol. 2014; 110(5):551-74. DOI: 10.1002/jso.23724. View

13.

Brisson M, Laprise J, Chesson H, Drolet M, Malagon T, Boily M . Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. J Natl Cancer Inst. 2015; 108(1). PMC: 6745694. DOI: 10.1093/jnci/djv282. View

14.

Chaturvedi A, Engels E, Pfeiffer R, Hernandez B, Xiao W, Kim E . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29(32):4294-301. PMC: 3221528. DOI: 10.1200/JCO.2011.36.4596. View

15.

Apter D, Wheeler C, Paavonen J, Castellsague X, Garland S, Skinner S . Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol. 2015; 22(4):361-73. PMC: 4375348. DOI: 10.1128/CVI.00591-14. View

16.

Guadagnolo B, Liu C, Cormier J, Du X . Evaluation of trends in the use of intensity-modulated radiotherapy for head and neck cancer from 2000 through 2005: socioeconomic disparity and geographic variation in a large population-based cohort. Cancer. 2010; 116(14):3505-12. DOI: 10.1002/cncr.25205. View

17.

Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans L, Curtis C, MacNeil J . National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2015. MMWR Morb Mortal Wkly Rep. 2016; 65(33):850-8. DOI: 10.15585/mmwr.mm6533a4. View

18.

Viens L, Henley S, Watson M, Markowitz L, Thomas C, Thompson T . Human Papillomavirus-Associated Cancers - United States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2016; 65(26):661-6. DOI: 10.15585/mmwr.mm6526a1. View

19.

Jacobson J, Epstein J, Eichmiller F, Gibson T, Carls G, Vogtmann E . The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid. Head Neck Oncol. 2012; 4:15. PMC: 3503554. DOI: 10.1186/1758-3284-4-15. View

20.

Harper D, Franco E, Wheeler C, Ferris D, Jenkins D, Schuind A . Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364(9447):1757-65. DOI: 10.1016/S0140-6736(04)17398-4. View